|Classification and external resources|
Magnetic resonance image in a person with neurocysticercosis showing many cysts within the brain.
|eMedicine||emerg/119 med/494 ped/537|
Cysticercosis is a tissue infection by the pork tapeworm (Taenia solium). People may have little or no symptoms for years, develop approximately one to two centimeter painless solid bumps in the skin and muscles, or have neurological symptoms if the brain is affected. After months or years these bumps can become painful and swollen then resolve. When cysts form in the brain it is known as neurocysticercosis. In the developing world this is one of the most common cause of seizures.
The disease is usually spread by eating foods that contains the tapeworm's eggs. The foods most commonly believed to be the cause are uncooked vegetables. The tapeworm eggs are from feces of a person infected with the adult worms. This infection is known as taeniasis and is when adult pork tapeworms live within the intestines. Taeniasis is due to eating cysts in poorly cooked pork. Both forms of infection can occur in the same person at the same time. The diagnosis can be made by aspiration of a cyst. Taking pictures of the brain with computer tomography (CT) or magnetic resonance imaging (MRI) is important for diagnosis disease in the brain. An increased number of white blood cell, called eosinophils, in the cerebral spinal fluid and blood may point to neurocysticercosis.
Preventing the infection involves: cooking pork well, proper toilets and improved access to clean water. Treating those with taeniasis is important to prevent spread. Treating disease that does not involve the nervous system may not be required. Treatment of those with neurocystercercosis may be with the medications praziquantel or albendazole. These may be required for long periods of time. Steroids may be needed to decrease inflammation during treatment. Anti-seizure medications may also be required. Surgery is sometimes done to remove the cysts. Seizures may occur in more than half of people who have cysts in their brain.
The pork tapeworm is common in many parts of the developing world including Asia, sub-Saharan Africa, and Latin America. In some areas it is believed that up to 25% of people are affected. In the developed world it is very uncommon. Worldwide as of 2010 it caused about 1,200 death up from 700 in 1990. Cysticercosis also affects pigs and cows but rarely causes symptoms as most do not live long enough. The disease has occurred in humans throughout history.
- 1 Signs and symptoms
- 2 Cause
- 3 Diagnosis
- 4 Prevention
- 5 Management
- 6 Epidemiology
- 7 History
- 8 Society and culture
- 9 References
Signs and symptoms
Cysticerci can develop in any voluntary muscle in humans. Invasion of muscle by cysticerci can cause myositis, with fever, eosinophilia, and muscular pseudohypertrophy, which initiate with muscle swelling and later progress to atrophy and fibrosis. In most cases, it is asymptomatic since the cysticerci die and become calcified.
The term neurocysticercosis is generally accepted to refer to cysts in the parenchyma of the brain. It presents with seizures and, less commonly, headaches. Cysticerca in brain parenchyma are usually 5–20 mm in diameter. In subarachnoid space and fissures, lesions may be as large as 6 cm in diameter and lobulated.
In some cases, cysticerci may be found in the globe, extraocular muscles, and subconjunctiva. Depending on the location, they may cause visual difficulties that fluctuate with eye position, retinal edema, hemorrhage, a decreased vision or even a visual loss.
Subcutaneous cysts are in the form of firm, mobile nodules, occurring mainly on the trunk and extremities. Subcutaneous nodules are sometimes painful.
The cause of human cysticercosis is the egg form of Taenia solium (pork tapeworm), which is transmitted through the oral fecal route. T. solium is a member of Phylum Platyhelminthes, class Cestoda, Order Cyclophyllidea and family Taeniidae. The common larval stage of T. solium was also known as Cysticercus cellulosae.
Humans are T. solium reservoirs. They are infected by eating undercooked pork that contains viable cysticerci. The cysticercus develops into an adult tape worm in the gut and produces large numbers of eggs which pass out in the feces. The presence of an adult tape worm in the gut is reasonably harmless. The condition known as cysticercosis in humans occurs due to the ingestion of tape worm eggs, either from external sources or from the person's own feces. The human has then become an accidental and "dead-end" intermediate host (that is, the infection can not progress any further). Pigs, which are the "normal" intermediate host for this parasite, get infected with cysticerci when they ingest human feces. The incubation period ranges from months to over ten years.
T. solium worms may reach a length of several meters. The scolex has four suckers, and a double crown of prominent hooks, which attach to the intestinal mucosa. T. solium eggs are spherical and 30 to 40 µm in diameter.
The cysticercus larva completes development in about 2 months. It is semitransparent, opalescent white, and elongate oval in shape and may reach a length of 0.6 to 1.8 cm.
The life cycle involves humans as a definite host and pigs as an intermediate host. Pigs ingest contaminated food or water that contains eggs or proglottids from human feces. The eggs (ova) develop into cysticerci in pig muscles. Humans become infected when they ingest raw or undercooked pork that contain viable cysticerci. Upon reaching the small intestine, the scolex attaches to the intestinal wall and a proglottid chain grows. T. solium releases three to six proglottids/day, bearing 30,000 to 70,000 eggs per proglottid into the intestine. Nearly 250,000 ova are passed daily into the human feces and to the environment, and the cycle continues. Infections with cysticercus occur after humans consume the ova from exogenous sources or through self-infection via the fecal-oral route. Humans, in this case, are intermediate hosts. Ova are digested in the stomach and release oncospheres which penetrate the intestinal wall and reach the bloodstream. These oncospheres develop into cysticerci in any organ but are common in brain, subcutaneous tissue, or eyes.
The traditional method of demonstrating tapeworm eggs or proglottids in stool samples diagnoses only taeniasis, carriage of the tapeworm stage of the life cycle. Only a small minority of patients with cysticercosis will harbor a tapeworm, rendering stool studies ineffective for diagnosis. Ophthalmic cysticercosis can be diagnosed by visualizing parasite in eye by fundoscopy.
Antibodies to cysticerci can be demonstrated in serum by EITB (Enzyme Linked Immunotransfer Blot) assay and in CSF by ELISA. An immunoblot assay using lentil-lectin (agglutinin from Lens culinaris) is highly sensitive and specific. However, Individuals with intracranial lesions and calcifications may be seronegative. In the CDC’s immunoblot assay, cysticercosis-specific antibodies can react with structural glycoprotein antigens from the larval cysts of T. solium. However, this is mainly a research tool not widely available in clinical practice and nearly unobtainable in resource limited settings.
The diagnosis of neurocysticercosis is mainly clinical, based on a compatible presentation of symptoms and findings of imaging studies.
Neuroimaging with CT or MRI is the most useful method of diagnosis. CT scan shows both calcified and uncalcified cysts, as well as distinguishing active and inactive cysts. Cystic lesions can show ring enhancement and focal enhancing lesions. Some cystic lesions, especially the ones in ventricles and subarachnoid space may not be visible on CT scan, since the cyst fluid is isodense with CSF. Thus diagnosis of extraparenchymal cysts usually relies on signs like hydrocephalus or enhanced basilar meninges. In such cases CT scan with intraventricular contrast or MRI can be used. MRI is more sensitive in detection of intraventricular cysts.
CSF findings include pleocytosis, elevated protein levels and depressed glucose levels; but these may not be always present.
Cysticercosis is considered as “tools-ready disease” according to WHO. International Task Force for Disease Eradication in 1992 reported that cysticercosis is potentially eradicable. It is feasible because there are no animal reservoirs besides humans and pigs. The only source of T. solium infection for pigs is from humans, a definite host. Theoretically, breaking the life cycle seems easy by doing intervention strategies from various stages in the life cycle.
- Massive chemotherapy of infected individuals, improving sanitation, and educating people are all major ways to discontinue the cycle, in which eggs from human feces are transmitted to other humans and/or pigs.
- Cooking of pork or freezing it and inspecting meat are effective means to cease the life cycle
- The management of pigs by treating them or vaccinating them is another possibility to intervene
- The separation of pigs from human faeces by confining them in enclosed piggeries. In Western European countries post World War 2 the pig industry developed rapidly and most pigs were housed. This was the main reason for pig cysticercosis largely being eliminated from the region. This of course is not a quick answer to the problem in developing countries.
The intervention strategies to eradicate cysticercosis includes surveillance of pigs in foci of transmission and massive chemotherapy treatment of humans. In reality, control of T. solium by a single intervention, for instance, by treating only human population will not work because the existing infected pigs can still carry on the cycle. The proposed strategy for eradication is to do multilateral intervention by treating both human and porcine populations. It is feasible because treatment pigs with oxfendazole have been shown to be effective and once treated, they are protected from further infections for at least 3 months.
Even with the concurrent treatment of humans and pigs, complete elimination is hard to achieve. In one study conducted in 12 villages in Peru, both humans and porcine were treated with praziquantel and oxfendazole, with the coverage of more than 75% in humans and 90% in pigs The result shows a decreased in prevalence and incidence in the intervention area; however the effect did not completely eliminate T. solium. The possible reason includes the incomplete coverage and re-infection. Even though T. solium could be eliminated through mass treatment of human and porcine population, it is not sustainable. Moreover, both tapeworm carriers of humans and pigs tend to spread the disease from endemic to non-endemic areas resulting in periodic outbreaks of cysticercosis or outbreaks in new areas.
Given the fact that pigs are part of a life cycle, vaccination of pigs is another feasible intervention to eliminate cysticercosis. Research studies have been focusing on vaccine against cestode parasites, since many immune cell types are found to be capable of destroying cysticercus. Many vaccine candidates are extracted from antigens of different cestodes such as T. solium, T. crassiceps, T. saginata, T. ovis and target oncospheres and/or cysticerci. In 1983, Molinari et al. reported the first vaccine candidate against porcine cysticercosis using antigen from cysticercus cellulosae drawn out from naturally infected. Recently, vaccines extracted from genetically engineered 45W-4B antigens have been successfully tested to pigs in an experimental condition. This type of vaccine can protect against cysticercosis in both Chinese and Mexican type of T. solium. However, it has not been tested in endemic field conditions, which is important because the realistic condition in the field differ greatly from experimental condition, and this can result in a great difference in the chances of infection and immune reaction.
Even though vaccines have been successfully generated, the feasibility of its production and usage in rural free ranging pigs still remains a challenge. If a vaccine is to be injected, the burden of work and the cost of vaccine administration to pigs will remain high and unrealistic. The incentives of using vaccines by pig owners will decrease if the vaccine administration to pigs takes time by injecting every single pig in their livestock. A hypothetical oral vaccine is proposed to be more effective in this case as it can be easily delivered to the pigs by food.
The vaccine constituted by 3 peptide synthetically produced (S3Pvac) has proven its efficacy in natural conditions of transmission. The S3PVAC vaccine so far, can be considered as the best vaccine candidate to be used in endemic areas such as Mexico (20). S3Pvac consists of three protective peptides: KETc12, KETc1 and GK1, whose sequences belong to native antigens that are present in the different developmental stages of T. solium and other cestode parasites.
Non-infected pigs from rural villages in Mexico were vaccinated with S3Pvac and the vaccine reduced 98% the number of cysticerci and 50% the number of prevalence. The diagnostic method involves necropsy and tongue inspection of pigs. The natural challenge conditions used in the study proved the efficacy of the S3Pvac vaccine in transmission control of T. solium in Mexico. The S3Pvac vaccine is owned by the National Autonomous University of Mexico and the method of high scale production of the vaccine has already been developed. The validation of the vaccine in agreement with the Secretary of Animal Health in Mexico is currently in the process of completion. It is also hoped that the vaccine will be well-accepted by pig owners because they also lose their income if pigs are infected cysticercosis. Vaccination of pigs against cysticercosis, if succeeded, can potentially have a great impact on transmission control since there is no chance of re-infection once pigs receive vaccination.
Cysticercosis can also be prevented by routine inspection of meat and condemnation of measly meat by the local government. However, in areas where food is scarce, cyst-infected meat might be considered as wasted since pork can provide high quality protein. At times, infected pigs are consumed within the locality or sold at low prices to traffickers who take the uninspected pigs at urban areas for sale.
Due to these limitations, cysticercosis has not been eliminated in any endemic areas.
Neurocysticercosis most often presents as hydrocephalus and acute onset seizures, thus the immediate mainstay of therapy is emergent reduction of intracranial pressure and anticonvulsant medications. Once the seizures have been brought under control, antihelminthic treatments may be undertaken. The decision to treat with antiparasitic therapy is complex and based on the stage and number of cysts present, their location, and the patient's specific clinical presentation. Antiparasitic treatment should be given in combination with corticosteroids and anticonvulsants to reduce inflammation surrounding the cysts and lower the risk of seizures. When corticosteroids are given in combination with praziquantel, cimetidine is also given, as corticosteroids decrease action of praziquantel by enhancing its first pass metabolism. Albendazole is generally preferable over praziquantel due to its lower cost and fewer drug interactions. Praziquantel can evoke an inflammatory response in CNS if hidden cystic lesion is present intracranially. Niclosamide can also be used.
Asymptomatic cysts, such as those discovered incidentally on neuroimaging done for another reason, may never lead to symptomatic disease and in many cases do not require therapy.
Calcified cysts have already died and involuted. Further antiparasitic therapy will be of no benefit.
Surgical intervention is much more likely to be needed in cases of intraventricular, racemose, or spinal neurocysticercosis. Treatments includes direct excision of ventricular cysts, shunting procedures, and removal of cysts via endoscopy.
Adult T. solium are easily treated with niclosamide, and is most commonly used in taeniasis. However cysticercosis is a complex disease and requires careful medication. Praziquantel (PZQ) is the drug of choice. In neurocysticercosis praziquantel is widely used. Albendazole appears to be more effective and a safe drug for neurocysticercosis. In complicated situation a combination of praziquantel, albendazole and steroid (such as corticosteroids to reduces the inflammation) is recommended. In the brain the cysts can be usually found on the surface. Most cases of brain cysts are found by accident, during diagnosis for other ailments. Surgical removals are the only option of complete removal even if treated successfully with medications.
In eye disease, surgical removal is necessary for cysts within the eye itself as treating intraocular lesions with anthelmintics will elicit an inflammatory reaction causing irreversible damage to structural components. Cysts outside globe can be treated with anthelmintics and steroids. Treatment recommendations for subcutaneous cysticercosis includes surgery, praziquantel and albendazole.
In general, subcutaneous disease does not need specific therapy. Painful or bothersome cysts can be surgically excised.
The tapeworm that causes cysticercosis is common to many parts of the world including China, Southeast Asia, India, sub-Saharan Africa, and Latin America. Worldwide as of 2010 it caused about 1,200 death up from 700 in 1990.
Some studies suggest that the prevalence of cysticercosis in Mexico is between 3.1 and 3.9 percent. Other studies have found the seroprevalence in areas of Guatemala, Bolivia, and Peru as high as 20 percent in humans, and 37 percent in pigs. In Ethiopia, Kenya and the Democratic Republic of Congo around 10% of the population is infected, in Madagascar 16%. The frequency has decreased in developed countries owing to stricter meat inspection, better hygiene and better sanitary facilities. The distribution of cysticercosis coincides with the distribution of T. solium. Cysticercosis is the most common cause of symptomatic epilepsy worldwide.
In Latin America, an estimated 75 million persons live in endemic areas and 400,000 people have symptomatic disease. Cysticercosis is also found to be associated with Hispanic ethnicity, immigrant status, and exposure to areas of endemicity. In the US, the disease is found in immigrants from Mexico, Central and South America. Current livestock for pigs in the U.S do not play a role in the transmission of Taenia solium, and thus cysticercosis in the U.S is an imported disease.
In the USA during 1990–2002, 221 cysticercosis deaths were identified. Mortality rates were highest for Latinos and men. The mean age at death was 40.5 years (range 2–88). Most patients, 84.6%, were foreign born, and 62% had emigrated from Mexico. The 33 US-born persons who died of cysticercosis represented 15% of all cysticercosis-related deaths. The cysticercosis mortality rate was highest in California, which accounted for 60% of all cysticercosis deaths.
The earliest reference to tapeworms were found in the works of ancient Egyptians that date back to almost 2000 BC. The description of measled pork in the History of Animals written by Aristotle (384–322 BC) showed that the infection of pork with tapeworm was known to ancient Greeks at that time. It was also known to Jewish and later to early Muslim physicians and has been proposed as one of the reasons for pork being forbidden by Jewish and Islamic dietary laws. Recent examination of evolutionary histories of hosts and parasites and DNA evidence show that over 10,000 years ago, ancestors of modern humans in Africa became exposed to tapeworm when they scavenged for food or preyed on antelopes and bovids, and later passed the infection on to domestic animals such as pigs.
Cysticercosis was described by Johannes Udalric Rumler in 1555; however, the connection between tapeworms and cysticercosis had not been recognized at that time. Around 1850, Friedrich Küchenmeister fed pork containing cysticerci of T. solium to humans awaiting execution in a prison, and after they had been executed, he recovered the developing and adult tapeworms in their intestines. By the middle of the 19th century, it was established that cysticercosis was caused by the ingestion of the eggs of T. solium.
Society and culture
- The first patient on the television show House (in the pilot episode) had cysticercosis.
- In the crossover of the series Grey's Anatomy (season 5, episode 15) and Private Practice (season 2), Archer Montgomery, brother of Addison Forbes Montgomery, suffered from neurocysticercosis. He was cured via the surgical removal of the cysts by his former brother-in-law Derek Shepherd.
- "Taeniasis/Cysticercosis Fact sheet N°376". World Health Organization. February 2013. Retrieved 18 March 2014.
- García, HH; Gonzalez, AE; Evans, CA; Gilman, RH; Cysticercosis Working Group in, Peru (Aug 16, 2003). "Taenia solium cysticercosis.". Lancet 362 (9383): 547–56. doi:10.1016/s0140-6736(03)14117-7. PMID 12932389.
- García HH, Evans CA, Nash TE, et al. (October 2002). "Current consensus guidelines for treatment of neurocysticercosis". Clin. Microbiol. Rev. 15 (4): 747–56. doi:10.1128/CMR.15.4.747-756.2002. PMC 126865. PMID 12364377.
- Bobes, RJ; Fragoso, G; Fleury, A; García-Varela, M; Sciutto, E; Larralde, C; Laclette, JP (Feb 18, 2014). "Evolution, molecular epidemiology and perspectives on the research of taeniid parasites with special emphasis on Taenia solium.". Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases. PMID 24560729.
- Lozano, R; Naghavi, M; Foreman, K; Lim, S; Shibuya, K; Aboyans, V; Abraham, J; Adair, T et al. (Dec 15, 2012). "Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010". Lancet 380 (9859): 2095–128. doi:10.1016/S0140-6736(12)61728-0. PMID 23245604.
- Markell EK, John DT, Krotoski WA. Medical Parasitology Eighth Edition. Pennsylvania: Saunders, 1999.
- Kerstein AH, Massey AD (2010). "Neurocysticercosis". Kansas Journal of Medicine 3 (4): 52–4.
- Suri A, Goel RK, Ahmad FU, Vellimana AK, Sharma BS, Mahapatra AK (Jan 2008). "Transventricular, transaqueductal scope-in-scope endoscopic excision of fourth ventricular neurocysticercosis: a series of 13 cases and a review.". Emerg Radiol. 1 (1): 35–9. doi:10.3171/ped-08/01/035.
- Hauptman JS, Hinrichs C, Mele C, Lee HJ (Apr 2005). "Radiologic manifestations of intraventricular and subarachnoid racemose neurocysticercosis.". J Neurosurg Pediatr 11 (3): 153–7. doi:10.1007/s10140-004-0383-y.
- Jang JW, Lee JK, Lee JH, Seo BR, Kim SH. (Mar 2010). "Recurrent primary spinal subarachnoid neurocysticercosis.". Spine 35 (5): E172–5. doi:10.1097/BRS.0b013e3181b9d8b6. PMID 20118838.
- Davis, LE. “Neurocysticercosis” Emerging Neurological Infections edited by Power, C and Johnson RT. Taylor & Francis Group, 2005. 261-287.
- Wortman PD. “Subcutaneous cysticercosis” J Am Acad Dermatol. 1991 (2 Pt 2): 409-14.
- Cheng, edited by Liang; Bostwick, David G. (2011). Essentials of anatomic pathology (3rd ed. ed.). New York: Springer. p. 395. ISBN 9781441960436.
- Reeder, P.E.S. Palmer, M.M. (2001). Imaging of tropicaldiseases : with epidemiological, pathological, and clinical correlation (2nd, rev. ed. ed.). Heidelberg, Germany: Springer-Verlag. p. 641. ISBN 9783540560289.
- al.], lead editors, Myron Yanoff, Jay S. Duker ; section editors, James J. Augsburger ... [et (2008). Ophthalmology (3rd ed. ed.). London: Elsevier Health Sciences. p. 835. ISBN 9780323076920.
- HH Garcia, R Araoz, RH Gilman, J Valdez, AE Gonzalez, C Gavidia, ML Bravo, and VC Tsang (1998). "Increased prevalence of cysticercosis and taeniasis among professional fried pork vendors and the general population of a village in the Peruvian highlands. Cysticercosis Working Group in Peru". Am. J. Trop. Med. Hyg. 59 (6): 902–905. PMID 9886197.
- WHO, “Global Plan to Combat Neglected Tropical Diseases 2008-2015. World Health Organization 2007
- CDC, International Task Force for Disease Eradication, 1992. MMWR weekly. 1992. 41(37); 691, 697-698. http://www.cdc.gov/mmwr/preview/mmwrhtml/00017648.htm
- Schantz, P. “Eradication of T. solium Cysticercosis” International Conference on Emerging Infectious Diseases 2002. CDC.ftp://ftp.cdc.gov/pub/infectious_diseases/iceid/2002/pdf/schantz.pdf
- Gonzalez AE, García HH, Gilman RH, Tsang VCW, Cysticercosis Working Group in Peru. “Control of Taenia solium” Acta Tropica 2003 87(1): 103-109.
- Gonzalez, A.E., Gavidia, C., Falcon, N., Bernal, T., Verastegui, M., Garcia, H.H., Gilman, R.H., Tsang, V.C., 2001.“Protection of pigs with cysticercosis from further infections after treatment with oxfendazole.” Am. J. Trop. Med. Hyg.65, 15-18.
- Garcia, H.H., 2002. “Effectiveness of an interventional control program for human and porcine Taenia solium cysticercosis in field conditions.” In: International Health. Johns Hopkins University, Baltimore, p. 250.
- Gilman, R.H., Garcia, H.H., Gonzalez, A.E., Dunleavy, M., Verastegui, M., Peru, T.C.W.G.I., 1999. Short cuts to development: methods to control the transmission of cysticercosis in developing countries. In: Garci´a, H.H., Marti´nez, M. (Eds.), Taenia solium taeniasis/cysticercosis. Editorial Universo, Lima,313-326.
- Margono, S.S., Subahar, R., Hamid, A., Wandra, T., Sudewi, S.S., Sutisna, P., Ito, A., 2001. “Cysticercosis in Indonesia: epidemiological aspects.” Southeast Asian J. Trop. Med.Public Health 32 (Suppl. 2), 79-84.
- Wandra, T., Subahar, R., Simanjuntak, G.M., Margono, S.S.,Suroso, T., Okamoto, M., Nakao, M., Sako, Y., Nakaya, K., Schantz, P.M., Ito, A., 2000. Resurgence of cases of epileptic seizures and burns associated with cysticercosis in Assologaima, Jayawijaya, Irian Jaya, Indonesia, 1991-1995. Trans. R. Soc. Trop. Med. Hyg. 94: 46-50.
- Sciutto E, Aluja Fragoso G., Hernandez M, Rosas G. Larralde (2008). "Vaccines Against Cisticercosis". Current Topics in Medicinal Chemistry 8 (5): 415–423. doi:10.2174/156802608783790839. PMID 18393905.
- Molinari J. L, Meza R, Suarez B, Palacios S, Tato P, Retana A. 1983 “Taenia solium : immunity in hogs to the Cysticercus.”Exp. Parasitol 55: 340-57.
- Luo X, Zheng Y, Hou J, Zhang S, Cai X. 2009 “Protection against Asiatic Taenia soliumInduced by a Recombinant 45W-4B Protein Clinical and Vaccine Immunology, 16 (2): 230-232.
- Huerta M, De Aluja AS, Fragoso G, Toledo A, Villalobos N, Hernandez M, Gevorkian G, Acero G, Diaz A et al. (2001). "Synthetic peptide vaccine against Taenia solium pig cysticercosis: successful vaccination in a controlled field trial in rural Mexico". Vaccine 20 (1–2): 262–6. doi:10.1016/S0264-410X(01)00249-3. PMID 11567772.
- Sciutto E, Morales J, Martinez JJ, Toledo A, Villalobos MN, Cruz-Revilla C, Meneses G, Hernandez M, Diaz A et al. (2007). "Further evaluation of the synthetic peptide vaccine S3Pvac against Taenia solium cysticercosis in pigs in an endemic town of Mexico". Parasitology 134 (Pt 1): 129–33. doi:10.1017/S0031182006001132. PMID 16948875.
- E-mail interview with Edda Sciutto. Feb 26 2009.
- CWGESA. 5th General Assembly of the Cysticercosis Working Group in Eastern and Southern Africa. 2007. CIRADhttp://pigtrop.cirad.fr/sp/recursos/publications/procedimientos/5th_general_assembly_of_the_cysticercosis_working_group_in_eastern_and_southern_africa
- Morales J, Martínez JJ, Garcia-Castella J,Peña N, Maza V, Villalobos N, Aluja AS, Fleury A, Fragoso G, Larralde C, Sciutto E. (2006) “Taenia solium: the complex interactions, of biological, social, geographical and commercial factors, involved in the transmission dynamics of pig cysticercosis in highly endemic areas” Annals of Tropical Medicine and Parasitology, 100(2) 123-135.
- White, Jr., A. Clinton (2009). "New developments in the management of neurocysticercosis". The Journal of Infectious Diseases 199 (9): 1261–2. doi:10.1086/597758. PMID 19358667.
- Dimitrios K. Matthaiou, Georgios Panos, Eleni S. Adamidi,Matthew E. Falagas “Albendazole versus Praziquantel in the Treatment of Neurocysticercosis: A Meta-analysis of Comparative Trials” PLoS Negl Trop Dis. 2008 March; 2(3): e194
- Pawlowski, Zbigniew S. (2006). "Role of chemotherapy of taeniasis in prevention of neurocysticercosis". Parasitology International 55: S105–S109. doi:10.1016/j.parint.2005.11.017. PMID 16356763.
- Garcia HH, Pretell EJ, Gilman RH, Martinez SM, Moulton LH, Del Brutto OH, Herrera G, Evans CA, Gonzalez AE, Cysticercosis Working Group in Peru. (2004). "A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis". N Engl J Med. 350 (3): 249–258. doi:10.1056/NEJMoa031294. PMID 14724304.
- Matthaiou DK, Panos G, Adamidi ES, Falagas ME. (2008). "Albendazole versus Praziquantel in the Treatment of Neurocysticercosis: A Meta-analysis of Comparative Trials". In Carabin, Hélène. PLOS Neglected Tropical Diseases 2 (3): e194. doi:10.1371/journal.pntd.0000194. PMC 2265431. PMID 18335068.
- "Taeniasis/Cysticercosis". World Health Organization. Retrieved 6 February 2014.
- Gutierrez, Yezid (2000). Diagnostic Pathology of Parasitic Infections with Clinical Correlations (2nd ed. ed.). New York [u.a.]: Oxford University Press. pp. 635–652. ISBN 9780195121438.
- Garcia HH, Gonzalez AE, Evans CA, Gilman RH. Cysticercosis Working Group in Peru. Taenia solium cystericercosis. Lancet 2003;362:547-556.
- International League Against Epilepsy. Relationship between epilepsy and tropical diseases. Epilepsia 1994;35:89-93.
- Bern C, Garcia HH, Evans C, Gonzalez AE, Verastegui M, Tsang VC, Gilman RH. “Magnitude of the disease burden from neurocysticercosis in a developing country.” Clin Infect Dis 1999 Nov 29 (5): 1203-9.
- Wadia, NH, Singh, G. “Taenia Solium: A Historical Note” Taenia Solium Cysticercosis: From Basic to Clinical Science CABI Publishing, 2002. 157-168.
- Ancient Hebrew Medicine<http://www.healthguidance.org/entry/6309/1/Ancient-Hebrew-Medicine.html>
- Oscar H. del Brutto, Brutto Et Al, Julio Sotelo, Gustavo C. Román (1998). Neurocysticercosis. Taylor and Francis. p. 3. ISBN 90-265-1513-8.
- Cox, F.E.G. “History of Human Parasitology” Clinical Microbiology Reviews. October 2002. 15(4) 595-612.
- Küchenmeister, F. The Cysticercus cellulosus transformed within the organism of man into Taenia solium. Lancet 1861 i:39.